Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Clinical Decision-Making
Combined Modality Therapy
Disease Management
Female
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Prognosis
Remission Induction
Survival Analysis
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome
Allogeneic hematopoietic stem cell transplantation
High-intensity chemotherapy
Philadelphia chromosome-negative acute lymphoblastic leukemia
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
11
06
2021
accepted:
21
07
2021
revised:
20
07
2021
pubmed:
31
7
2021
medline:
17
12
2021
entrez:
30
7
2021
Statut:
ppublish
Résumé
The optimal treatment for Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) has not been established in the high-intensity chemotherapy era. The outcomes of patients with Ph-negative ALL who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-matched related or unrelated donor in CR1 (HSCT-MRD group and HSCT-MUD group) were obtained from a Japanese registry database. Patients aged 16-24 years and 25-65 years were analyzed separately, and their outcomes were compared to those of patients who continued high-intensity chemotherapy in CR1 in studies (202U group and 202O group) by the Japan Adult Leukemia Study Group (JALSG). In the HSCT-MRD group, patients younger than 25 years had lower overall survival (OS) than the 202U group, presumably due to the higher non-relapse mortality (NRM) in the HSCT-MRD group. Patients 25 years and older had similar OS to the 202O group. The lower relapse rate was counterbalanced by higher NRM in the HSCT-MRD group. In the HSCT-MUD group, patients in both age groups had similar OS to their corresponding groups in the JALSG studies. In conclusion, high-intensity chemotherapy may change the role of HSCT for Ph-negative ALL.
Identifiants
pubmed: 34328634
doi: 10.1007/s12185-021-03198-4
pii: 10.1007/s12185-021-03198-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
608-619Subventions
Organisme : japan agency for medical research and development
ID : JP19ck0106331
Organisme : japan agency for medical research and development
ID : 19ek0510023h0002
Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Takahashi S, et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia. 2011;25:259–65.
doi: 10.1038/leu.2010.260
Kako S, Morita S, Sakamaki H, Iida H, Kurokawa M, Miyamura K, et al. The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis. Bone Marrow Transplant. 2013;48:1077–83.
doi: 10.1038/bmt.2013.4
Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002;16:1259–66.
doi: 10.1038/sj.leu.2402526
Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, et al. Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. Int J Hematol. 2010;92:490–502.
doi: 10.1007/s12185-010-0672-z
Sallan SE. Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology. 2006;2006:128–32.
doi: 10.1182/asheducation-2006.1.128
Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014;4:e252.
doi: 10.1038/bcj.2014.72
Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–8.
doi: 10.1200/JCO.2008.18.6916
Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. 2018;32:626–32.
doi: 10.1038/leu.2017.283
Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548–59.
doi: 10.1182/blood-2018-10-881961
Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.
doi: 10.1007/s12185-015-1894-x
Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11–9.
doi: 10.1007/s12185-015-1907-9
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994;12:2580–7.
doi: 10.1200/JCO.1994.12.12.2580
Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group Blood. 1995;86:1619–28.
pubmed: 7632972
Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–86.
doi: 10.1200/JCO.2004.10.050
Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028–37.
doi: 10.1182/blood-2003-10-3560
Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–33.
doi: 10.1182/blood-2007-10-116582
Cornelissen JJ, van der Holt B, Verhoef GE, van Veer MB, van Oers MH, Schouten HC, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 2009;113:1375–82.
doi: 10.1182/blood-2008-07-168625
Ribera J-M, Morgades M, Ciudad J, Montesinos P, Barba P, García-Cadenas I, et al. Post-remission treatment with chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with high-risk (HR) Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) according to their minimal residual disease (MRD). Final results of the pethema ALL-HR-11 trial. Blood. 2019;134:826.
doi: 10.1182/blood-2019-123613
Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01213-5 .
doi: 10.1038/s41375-021-01213-5
pubmed: 34088982
pmcid: 8329698
Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, et al. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016;91:322–9.
doi: 10.1002/ajh.24285
Wieduwilt MJ, Stock W, Advani AS, Luger SM, Larson RA, Tallman MS, et al. Superior survival with post-remission pediatric-inspired chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: comparison of CALGB 10403 to patients reported to the CIBMTR. Blood. 2019;134:261.
doi: 10.1182/blood-2019-128560
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53.
doi: 10.1056/NEJMoa1509277
Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47.
doi: 10.1056/NEJMoa1609783
Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.
doi: 10.1056/NEJMoa1709919
Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121:339–50.
doi: 10.1182/blood-2012-07-445098
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.
doi: 10.1053/bbmt.2003.50026
Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, et al. A prospective, longitudinal observation of the incidence, treatment, and survival of late acute and chronic graft-versus-host disease by National Institutes of Health Criteria in a Japanese Cohort. Biol Blood Marrow Transplant. 2020;26:162–70.
doi: 10.1016/j.bbmt.2019.09.016
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.
doi: 10.1182/blood-2008-11-185132
Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–76.
doi: 10.1182/blood-2011-09-377713
Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–49.
doi: 10.1182/blood-2014-01-547695
Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.
doi: 10.1001/jamaoncol.2017.0580
Nagafuji K, Miyamoto T, Eto T, Ogawa R, Okumura H, Takase K, et al. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. Eur J Haematol. 2019;103:164–71.
doi: 10.1111/ejh.13268
Herold T, Gokbuget N. Philadelphia-like acute lymphoblastic leukemia in adults. Curr Oncol Rep. 2017;19:31.
doi: 10.1007/s11912-017-0589-2
Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486–96 (quiz 586).
doi: 10.1182/blood-2014-09-599894